The biopharma market is evolving rapidly. From the GLP‑1 surge to pricing reforms and the rise of advanced modalities, 2026 will challenge industry players to think strategically about revenue, margins, and market share. Companies that anticipate regulatory revisions, de-risk supply, and deliver tailored solutions will gain a clear competitive edge.
For biopharma leaders, the challenge is threefold: meeting unprecedented demand while minimizing risk, controlling costs, and navigating complex regulatory and supply-chain landscapes. Success in 2026 will favor those who partner with suppliers capable of delivering operational clarity, continuity, and tailored support, turning disruption into sustainable business growth.
The rapid rise of anti-obesity and diabetes therapies, led by next-generation oral GLP-1s and injectables, is reshaping the fundamentals of biopharma manufacturing. Beyond headline demand, these therapies introduce structural supply pressure, driven by material-intensive processes that dramatically increase requirements for solvents, intermediates, excipients, and specialty inputs; pressures that will only intensify as oral dosage forms scale.
“What we’re seeing is a shift from episodic sourcing to long-term supply strategy,” says Daniel Valentino, Global Sales Director at BrandNu. Drawing on more than 30 years of customer-centric leadership across the life sciences including building global account strategies, navigating complex supply negotiations, and scaling commercial models, Valentino brings a pragmatic lens to the challenge. As the subsidiary leading Caldic’s Biopharma business, BrandNu leverages this experience to align global sourcing, custom formats, and ready-to-use solutions, helping customers secure reliable access, manage cost, and meet accelerating market demand without compromising quality or continuity.
Antibody-drug conjugates (ADCs) and cell & gene therapies (CGTs) present exciting opportunities and supply challenges. John Hodges, Business Development Manager who joined BrandNu in September 2025, explains how his cGMP and production-scale expertise acquired in prior roles is instrumental in supporting customers navigate across ADC and CGT supply challenges. “ADCs and CGTs are growing fast, and they bring supply challenges. The Caldic Biopharma offering includes cGMP-compliant chemical raw materials with full traceability, change notification, custom packaging & blending services, and dual-source options to mitigate single-sourcing risks. In short, we streamline operation efficiencies and reduce costs for our clients, allowing them to focus on innovation. By understanding exactly how our customers use these materials, we position ourselves as a partner that helps mitigate risk and accelerate production.”
“At, Caldic, we go beyond supplying high-purity raw materials and custom formulations. We deliver predictability, flexibility, and operational efficiency."
Daniel Valentino adds, “At, Caldic, we go beyond supplying high-purity raw materials and custom formulations. We deliver predictability, flexibility, and operational efficiency. By understanding exactly how our customers use their materials, we provide solutions that remove risk, reduce lead times, and improve yield. We take a proactive approach, mapping key brands, securing alternative sources, and preparing filing-ready packages so our customers can meet ambitious growth targets without disruption.”
Lou Avvisati emphasizes, “In today’s competitive biopharma market, continuity of supply is a strategic imperative. By combining deep process understanding with flexible, tailored solutions, we help our customers excel in their core operations and strengthen supply reliability. We enable them to focus on what they do best: bringing innovative therapies to market quickly, efficiently, and reliably. In 2026, success will favor those who anticipate market shifts, adapt quickly, and partner with suppliers who deliver more than just products. At Caldic, we deliver continuity.”
This customer-centric profile is increasingly recognized by leading global biopharma manufacturers, who view Caldic as a benchmark for service quality, transparency, and reliability. One of the top-ten global biopharma companies and BrandNu customers recognizes the company as the ‘gold standard’ among suppliers. From real-time communication to rapid resolution of quality events, excellent execution translates directly into reduced risk and greater confidence at scale, resulting in a top-tier ranking. A true testament to the unique care provided to partners, suppliers and customers alike, across Caldic subsidiaries worldwide.
I biofarmaceutici stanno ridefinendo l’assistenza ai pazienti con terapie mirate che salvano vite. In Caldic alimentiamo l’innovazione in biologici, biosimilari e sistemi avanzati di somministrazione di farmaci offrendo ingredienti specializzati, supporto alla formulazione e servizi certificati GMP su misura per rispondere alle normative globali.
